Browsing
     by title


0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

or enter first few letters:   
OK
Full Text
Peer Reviewed
See detailPrévention et traitement des nausées et vomissements après chimiothérapie anticancéreuse
Brasseur, Edmond ULg; Silvestre, Rose-Marie; Jerusalem, Guy ULg et al

in Médecine et Hygiène (2002), 60

Detailed reference viewed: 72 (6 ULg)
Full Text
See detailPrévention et traitement des radiodermites.
Henry, Frédérique ULg; Uhoda, Emmanuelle ULg; Pierard, Gérald ULg

in Skin (2008), 11

Les radiodermites sont variables tant par leur nature que par leur intensité. De nombreuses tentatives de prévention ou de traitement de ces effets cutanés indésirables ont été rapportées dans la ... [more ▼]

Les radiodermites sont variables tant par leur nature que par leur intensité. De nombreuses tentatives de prévention ou de traitement de ces effets cutanés indésirables ont été rapportées dans la littérature. Leur efficacité est variable et souvent infondée ou décevante. Une information du patient et une approche multidisciplinaire sont souhaitables pour la prise en charge des radiodermites. [less ▲]

Detailed reference viewed: 114 (4 ULg)
Full Text
Peer Reviewed
See detailLa prévention médicalisée est-elle néfaste pour nos patients ? Et à quelles conditions leur serait-elle bénéfique ?
Vanmeerbeek, Marc ULg

Conference (2009, June 25)

En examinant nos pratiques en prévention, il semble nécessaire de mieux asseoir la validité scientifique de nos actes, e.a. en prenant de la distance par rapport aux pressions commerciales. Il serait ... [more ▼]

En examinant nos pratiques en prévention, il semble nécessaire de mieux asseoir la validité scientifique de nos actes, e.a. en prenant de la distance par rapport aux pressions commerciales. Il serait utile de rapprocher la médecine générale et la santé publique, en augmentant la place de la promotion de la santé et ne développant la place du patient. De nouvelles tâches sont à imaginer dans un partenariat multidisciplinaire. [less ▲]

Detailed reference viewed: 23 (3 ULg)
Peer Reviewed
See detailPrevention of Aorta-Coronary Bypass Graft Occlusion. Beneficial Effect of Ticlopidine on Early and Late Patency Rates of Venous Coronary Bypass Grafts: A Double-Blind Study
Limet, Raymond ULg; David, Jean-Louis ULg; Magotteaux, Paul ULg et al

in Journal of Thoracic and Cardiovascular Surgery (The) (1987), 94(5), 773-83

The efficacy of coronary bypass grafting obviously being linked to graft patency, it is compulsory to look for any innovation that could improve the patency rate. Ticlopidine, an antiplatelet drug, was ... [more ▼]

The efficacy of coronary bypass grafting obviously being linked to graft patency, it is compulsory to look for any innovation that could improve the patency rate. Ticlopidine, an antiplatelet drug, was tested against placebo in a double-blind trial: 173 patients (475 grafts) subjected to venous coronary artery bypass grafting were randomly treated with ticlopidine (250 mg twice daily) or placebo from the second postoperative day for 12 months. Graft patency was assessed by digital angiography on days 10 (99.4% of the patients), 180 (98.2%), and 360 (91.7%). The effect of treatment on platelet aggregation and bleeding time were measured concomitantly; a clear-cut effect was demonstrated at each interval. Intention-to-treat graft-by-graft analysis shows that ticlopidine significantly reduced the graft occlusion rate on day 10 (7.1% versus 13.4%, p less than 0.05), day 180 (15.0% versus 24.0%, p less than 0.02), and day 360 (15.9% versus 26.1%, p less than 0.01). Sequential grafts to the left anterior descending coronary artery, with side-to-side anastomosis to diagonal branch(es), are less frequently occluded than individual grafts. On the contrary, grafts to endarterectomized vessels occlude more frequently. Individual patient-by-patient analysis shows that patency of all grafts at each study time, is more frequent in the ticlopidine group. The difference is significant when one considers patients without sequential or endarterectomized grafts. The difference is also present at each study time: day 10 (84.4% versus 66.7%, p less than 0.05), day 180 (74.4% versus 52.3%, p less than 0.05) and day 360 (75.0% versus 52.5%, p less than 0.05). Results are even more impressive if one excludes from analysis the four patients in the ticlopidine group in whom administration of the drug was delayed. This supports previous suggestions that early therapy is necessary. These results show that graft occlusion occurs mainly in the first 6 postoperative months. The incidence of occlusion is significantly reduced by ticlopidine therapy. [less ▲]

Detailed reference viewed: 5 (0 ULg)
Full Text
Peer Reviewed
See detailPrevention of bacterial biofilms by covalent immobilization of peptides onto plasma polymer functionalized substrates
Vreuls, Christelle ULg; Zocchi, Germaine ULg; Thierry, Benjamin et al

in Journal of Materials Chemistry (2010), 20

In this study, robust antibacterial coatings were created on stainless steel through the covalent grafting of antibacterial peptides onto an organic-polymeric interlayer deposited by RF-glow discharge ... [more ▼]

In this study, robust antibacterial coatings were created on stainless steel through the covalent grafting of antibacterial peptides onto an organic-polymeric interlayer deposited by RF-glow discharge plasma. X-Ray photoelectron spectroscopy was used to characterize and optimize the two steps of the coating process. The biocidal activity of these surfaces was demonstrated against both Gram+ and Gram- bacteria using ISO tests. 3 to 6 log10 reductions of both Gram+ and Gram- bacterial strains were obtained compared to uncoated stainless steel and depending on the particular antibacterial peptide immobilized. Importantly the antibacterial surfaces were resistant to several cleaning conditions. The latter is significant as the stability of such antibacterial surfaces in close to real life conditions is a major concern and leaching, de-lamination, rearrangement and ageing of the coating can lead to insufficient long term biofilm resistance of the surface. [less ▲]

Detailed reference viewed: 46 (9 ULg)
Peer Reviewed
See detailPrevention of bacterial biofilms onto stainless steel substrates by immobilization of antimicrobial and anti-biofilm biomolecules
Vreuls, Christelle ULg; Zocchi, Germaine ULg; Faure, Emilie ULg et al

Conference (2011)

Stainless steel is widely used in the daily life in building and food industries as well as in the medical field. However, at long term, bacteria succeed in adhering, proliferating and forming a resistant ... [more ▼]

Stainless steel is widely used in the daily life in building and food industries as well as in the medical field. However, at long term, bacteria succeed in adhering, proliferating and forming a resistant biofilm on stainless steel. Therefore, surface modification is needed providing metal surface with antibacterial, anti-adhesion and easy cleaning properties. Several biomolecules (antimicrobial peptides, antiadhesion biomolecules and anti-biofilm enzymes) were immobilized on stainless steel thanks to different immobilization techniques. In a first approach, cationic peptides have been embedded in a LBL architecture comprising anti-adhesion biomolecules. In a second approach, small inorganic-binding peptides isolated by phage display technology and recognizing specifically the steel surface were used as linker for antimicrobial peptide immobilization. Finally, antibacterial peptides were covalently grafted onto an organic-polymeric interlayer deposited by plasma. Resulting antibacterial, antiadhesion and anti-biofilm properties were characterized and the advantages of each immobilization technique were documented. The biocidal effect of these surfaces was demonstrated against Gram+/- bacteria. Coated stainless steel surfaces led to 95% reduction of S. epidermidis adhesion vs bare substrate. By combining both antibacterial and anti-adhesion biomolecules, we produced stainless steel surfaces with better cleanability. A biofilm-releasing glycoside hydrolase was also immobilized on the surface and showed to confer anti-biofilm properties to stainless steel. Moreover, we provide valuable insight about the resistance of the coating to close to real life cleaning conditions. [less ▲]

Detailed reference viewed: 376 (7 ULg)
Full Text
Peer Reviewed
See detailPrevention of cardiovascular disease: plea for a rationale use of diet and lipid-lowering drugs.
Scheen, André ULg

in Acta Clinica Belgica (2003), 58(3), 149-51

Detailed reference viewed: 12 (0 ULg)
Full Text
See detailprevention of delirium in perioperatie cares in old persons
Petermans, Jean ULg

Conference (2012, November 10)

Detailed reference viewed: 11 (2 ULg)
Peer Reviewed
See detailPrevention of early postmenopausal bone loss by intranasal calcitonin - a controlled, randomised study lasting one year in normal women
Reginster, Jean-Yves ULg; Denis, D; Albert, Adelin ULg et al

in Gynecological Endocrinology : The Official Journal of the International Society of Gynecological Endocrinology (1988), 2

Detailed reference viewed: 14 (3 ULg)
Full Text
Peer Reviewed
See detailPrevention of early postmenopausal bone loss by strontium ranelate : a randomised, two-year, double-blind, placebo-controlled trial
Reginster, Jean-Yves ULg; DEROISY, Rita ULg; Tsouderos, Y et al

in Journal of Bone and Mineral Research (2001), 16(S1), 219

Detailed reference viewed: 11 (1 ULg)
Full Text
Peer Reviewed
See detailPrevention of early postmenopausal bone loss by strontium ranelate: The randomized, two-year, double-masked, dose-ranging, placebo-controlled PREVOS trial
Reginster, Jean-Yves ULg; Deroisy, Rita ULg; Dougados, M. et al

in Osteoporosis International (2002), 13(12), 925-931

Early postmenopausal women (n = 160) were randomised to receive placebo or strontium ranelate (SR) 125 mg/day, 500 mg/day or 1 g/day for 2 years (40 participants per group). All participants received ... [more ▼]

Early postmenopausal women (n = 160) were randomised to receive placebo or strontium ranelate (SR) 125 mg/day, 500 mg/day or 1 g/day for 2 years (40 participants per group). All participants received calcium 500 mg/day. The primary efficacy parameter was the percent variation in lumbar bone mineral density (BMD), measured using dual-energy X-ray absorptiometry. Secondary efficacy criteria included hip BMD and biochemical markers of bone turnover. At month 24, SR I g/day significantly increased lumbar BMD compared with placebo [mean (SD) +5.53% (5.12); p < 0.001] for measured values and [mean (SD) + 1.41% (5.33%); p < 0.05] for values adjusted for bone strontium content. The annual increase for adjusted values was +0.66% compared with -0.5% with placebo, with an overall beneficial effect after 2 years of about 2.4% with SR I g/day relative to placebo. There were no other significant between-group differences in adjusted lumbar BMD. Femoral neck and total hip BMD were also significantly increased at month 24 with SR I g/day compared with placebo [mean (SD): +2.46% (4.78) and +3.21% (4.68), respectively; both p < 0.001)]. SR 1 g/day significantly increased bone alkaline phosphatase at all time points (p < 0.05) compared with baseline and between-group analysis showed a significant increase, compared with placebo, at month 18 (p = 0.048). No effect on markers of bone resorption was observed. SR was as well tolerated as placebo. The minimum does at which SR is effective in preventing bone loss in early postmenopausal non-osteoporotic women is therefore 1 g/day. [less ▲]

Detailed reference viewed: 10 (2 ULg)
Full Text
Peer Reviewed
See detailPrevention of early postmenopausal bone loss with oral tiludronate
Roux, C; DEROISY, Rita ULg; Basse-Cathalinat, B et al

in Osteoporosis International (1996), 6(S1), 249

Detailed reference viewed: 23 (2 ULg)
Full Text
Peer Reviewed
See detailPrevention of falls, bone loss and fractures : D-hormone analogs or native vitamin D? a meta-perspective
Richy, Florent; Dukas, L.; Reginster, Jean-Yves ULg

in Osteoporosis International (2009, March), 20(Suppl.1), 90

Detailed reference viewed: 9 (1 ULg)
See detailPrevention of GBS perinatal infections: guidelines and update
Melin, Pierrette ULg

Conference (2007, September 27)

Detailed reference viewed: 9 (1 ULg)
Full Text
Peer Reviewed
See detailPrevention of group B streptococcal neonatal disease revisited. The DEVANI European project
Rodriguez-Granger, J.; Alvargonzales, J. C.; Berardi, A. et al

in European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology (2012)

The purpose of this paper was to present the current knowledge on the prevention of group B streptococcus (GBS)neonatal infections and the status of prevention policies in European countries and to ... [more ▼]

The purpose of this paper was to present the current knowledge on the prevention of group B streptococcus (GBS)neonatal infections and the status of prevention policies in European countries and to present the DEVANI pan-European program, launched in 2008. The aim of this program was to assess the GBS neonatal infection burden in Europe, to design a new vaccine to immunize neonates against GBS infections, to improve the laboratory performance for the diagnosis of GBS colonization and infection, and to improve the methods for the typing of GBS strains. The current guidelines for GBS prevention in different countries were ascertained and a picture of the burden before and after the instauration of prevention policies has been drawn. After the issue of the Centers for Disease Control and Prevention (CDC) guidelines, many European countries have adopted universal screening for the GBS colonization of pregnant women and intrapartum prophylaxis to colonized mothers. Nevertheless, some European countries continue advocating the risk factor approach to GBS prevention. Most European countries have implemented policies to prevent GBS neonatal infections and the burden of the disease has decreased during the last several years. Nevertheless, further steps are necessary in order to develop new strategies of prevention, to improve microbiological techniques to detect GBS colonization and infection, and to coordinate the prevention policies in the EU. [less ▲]

Detailed reference viewed: 26 (3 ULg)
See detailPrevention of hamstring injuries in football players
Croisier, Jean-Louis ULg

in Congress book of Brucosport – 23rd Congress of Sports Medicine of the AZ Sint-Jan AV (2004, October 15)

Detailed reference viewed: 27 (1 ULg)
Full Text
Peer Reviewed
See detailPrevention of hip fractures in osteoporosis
Neuprez, Audrey ULg; Hiligsmann, Mickaël ULg; Bruyère, Olivier ULg et al

in Minerva Ortopedica e Traumatologica (2007), 58(5), 423-437

Hip fracture is the major clinical consequence of osteoporosis. It is linked with decreased life expectancy and quality of life, placing an ever increasing burden on health services. Few medications have ... [more ▼]

Hip fracture is the major clinical consequence of osteoporosis. It is linked with decreased life expectancy and quality of life, placing an ever increasing burden on health services. Few medications have unequivocally demonstrated their ability to reduce hip fracture risk in osteoporotic subjects. Daily alendronate and risedronate reduce hip fracture in patients with low bone mineral density and prevalent vertebral fractures. Intravenous bisphosphonates have been developed, in response to long-term poor adherence to oral anti-osteoporotic treatments. Once-yearly zoledronic acid reduces fracture rates at the spine, non-spine and hip locations. Strontium ranelate, the first drug to uncouple bone formation from bone resorption has also demonstrated its ability to reduce hip fractures in patients above 74 years old, with prevalent low bone mineral density. Calcium and vitamin D supplementation are prerequisite for the management of elderly subjects and should always been associated to anti-resorptive or bone forming agents. Non-pharmacological management of osteoporosis is recommended cannot be considered a substitute for pharmacological treatment of osteoporosis, not even in old age. [less ▲]

Detailed reference viewed: 101 (10 ULg)
Peer Reviewed
See detailPrevention of human errors
Nyssen, Anne-Sophie ULg

Conference (2003, September)

Detailed reference viewed: 4 (1 ULg)